Influenza or flu is a

Similar documents
Infectious Diseases. Antibodies and antigens

2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit

Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set

Influenza A H1N1 HA ELISA Pair Set

The "Flu" a case of low fever and sniffles that keeps you home in bed for a day a gastrointestinal upset ("stomach flu")

What is Influenza? Patricia Daly MD, FRCPC Medical Health Officer and Medical Director of Communicable Disease Control

Cover Page. The handle holds various files of this Leiden University dissertation

Reagents for the Typing of Human Influenza Isolates 2011

Centers for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*

Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity

Recommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness

This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for

Metabolic Syndrome. Antibodies and antigens

Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso

H5N1 ( Avian Flu ) Hemagglutinin ELISA Pair Set

Incorporating virologic data into seasonal and pandemic influenza vaccines

Recommended composition of influenza virus vaccines for use in the influenza season

Influenza A H7N9 (A/Anhui/1/2013) Hemagglutinin / HA ELISA Pair Set

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination

REAGENTS FOR THE TYPING OF HUMAN INFLUENZA ISOLATES 2017

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

Rapid-VIDITEST. Influenza A

Human Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١

Acute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).

2009 (Pandemic) H1N1 Influenza Virus

Flu, Avian Flu and emerging aspects (H1N1 resistance)

HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)

Broadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University

Original Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus

Ralph KY Lee Honorary Secretary HKIOEH

Laboratory Diagnosis of Viral Infections affect the Lower Respiratory Tract. M Parsania, Ph.D. Tehran Medical Branch, Islamic Azad University

INFLUENZA-2 Avian Influenza

Human Influenza A (Swine Flu) Rapid test

Identification of Microbes Lecture: 12

Update on influenza monitoring and vaccine development

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

ENZYME IMMUNOASSAYS FOR THE DIAGNOSIS OF CHLAMYDIA INFECTIONS. Chlamydia sp. Chlamydia pneumoniae Chlamydia trachomatis INFECTIOUS SEROLOGY

Update I had a little bird, It s name was Enza, I opened up the window, And In Flu Enza.

Ralf Wagner Paul-Ehrlich-Institut

Orthomyxoviridae and Paramyxoviridae. Lecture in Microbiology for medical and dental medical students

The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses

Pandemic Influenza influenza epidemic: realization of a worst-case scenario

PUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA

Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set

Respiratory Viruses. Respiratory Syncytial Virus

Centers for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*

INFLUENZA EVOLUTION: Challenges for diagnosis

In the Name of God. Talat Mokhtari-Azad Director of National Influenza Center

INFLUENZA A VIRUS. Structure of the influenza A virus particle.

Dr Olga Pleguezuelos CSO and Project Manager at SEEK

University of Groningen

Nanoparticulate Vaccine Design: The VesiVax System

Isolation of H9N2 Subtype of Avian Influenza Viruses during an Outbreak in Chickens in Iran

Rapid-VIDITEST Swine Flu

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Influenza: Seasonal, Avian, and Otherwise

Isolation of Panels of Llama Single-Domain Antibody Fragments Binding All Nine Neuraminidase Subtypes of Influenza A Virus

Influenza 2009: Not Yet The Perfect Storm

Laboratory Diagnosis of Viral. Tehran Medical Branch, Islamic Azad University

Q: If antibody to the NA and HA are protective, why do we continually get epidemics & pandemics of flu?

Avian Influenza (Bird Flu) Fact Sheet

دکتر بهروز نقیلی استاد بیماریهای عفونی مرکس تحقیقات بیماریهای عفونی و گرمسیری پاییس 88

Active and Passive Immunization for Avian Influenza Virus Infections

ORTHOMYXOVIRUSES INFLUENZA VIRUSES. (A,B and C)

Respiratory Syncytial Virus. Respiratory Syncytial Virus. Parainfluenza virus. Acute Respiratory Infections II. Most Important Respiratory Pathogens

human Total Cathepsin B Catalog Number: DY2176

PRODUCTS CATALOG OUR MISSION:

Current Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?

ENZYME IMMUNOASSAYS AND AGGLUTINATION FOR THE DIAGNOSIS OF PERTUSSIS AND PARAPERTUSSIS

Influenza: The Threat of a Pandemic

VIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks

point-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital

Influenza Infection In Human. Dr. Zuhaida A. Jalil Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018

Influenza B Hemagglutinin / HA ELISA Pair Set

LECTURE OUTLINE. B. AGENT: Varicella-zoster virus. Human herpes virus 3. DNA virus.

Original Article Polyclonal Antibody against Recombinant Nucleoprotein of the Influenza A Virus (H1N1); Production and Purification

Tis the Season Respiratory that is

Laboratory Diagnosis of Avian Influenza and Newcastle Disease

Influenza. By Allison Canestaro-Garcia. Disease Etiology:

Vaccine Technology II June 1-6, 2008 (Albufeira, Algarve, Portugal) FluBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine.

Time-Resolved Fluoroimmunoassay with Monoclonal Antibodies for Rapid Diagnosis of Influenza Infections

Evolution of influenza

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

Viral Infections of the Respiratory System. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

Correlates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer

Mouse C3 (Complement Factor 3) ELISA Kit

Conflict of Interest and Disclosures. Research funding from GSK, Biofire

INFLUENZA. By :Nader Alaridah MD, PhD

Viruses: Select Agents and Emerging Pathogens. Patricia Bolívar MS., CLS, PHM

Overview of assays for influenza vaccines immunology evaluation

Rapid-VIDITEST. Influenza A+B

Where Health Care Meets Policy. with Dr. Mike Magee

Reporting of Severe and Fatal Pediatric Influenza New Jersey Department of Health Influenza Season

J07 Titer dynamics, complement fixation test and neutralization tests

TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet

MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION

Strategies for containing an emerging influenza pandemic in South East Asia 1

Mitochondrial Trifunctional Protein (TFP) Protein Quantity Microplate Assay Kit

Influenza Testing Today: Keeping Up with a Moving Target

Transcription:

Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal epidemics in human beings on an annual basis. Furthermore, influenza A is also responsible for the pandemics that periodically appear, the most recent one being that which was caused by a H1N1 strain in 09. The illnesses range from mild to severe. According to WHO, the annual epidemics result in several million cases of severe illnesses and approximately 250,000 to 500,000 deaths per year worldwide. Severe cases and deaths mostly occur among the people in highrisk groups, e.g. young children, pregnant women, people aged over 65 years and those who suffer from certain medical conditions. Influenza diagnostic tests are based on various technologies from viral isolation to immunodiagnostic and molecular diagnostic methods. Immunodiagnostic tests, especially rapid influenza diagnostic tests (RIDTs) that utilize monoclonal antibodies (MAbs) are often the test of choice due to their ease-of-use and low cost, although the sensitivities of the tests do vary significantly. Biochemistry of influenza viruses type A and type B The influenza viruses type A and type B are negativesense single-stranded RNA viruses that belong to the family of Orthomyxoviridae. These enveloped viruses are usually spherical and -100 nm in diameter. The ssrna is found in ribonucleoparticle complexes that are associated with RNA-dependent polymerase and nucleoprotein (NP). NP is a structural protein that is one of the main determinants of the virus type (A, B or C). Two other important antigens are haemagglutinin (HA) and neuraminidase (NA). Both of these are glycoproteins and they are found on the surface of the virus. The influenza A viruses are divided into subtypes based on the variations in the HA and NA proteins. There are 18 known types of hemagglutinin and 11 known types of neuraminidase. H1N1 and H3N2 strains are currently circulating as seasonal influenza A viruses. The influenza B viruses are not divided into subtypes. They are instead named after the areas where they were first identified. Reagents for the development of immunoassays for the detection of influenza viruses We provide a broad selection of MAbs with different specificities that enable the detection of influenza A and influenza B from clinical samples. In addition, we provide several strains of inactivated viruses as antigens. Influenza A monoclonal antibodies We provide several highly sensitive and specific monoclonal antibodies for the detection of the influenza A virus. MAbs are suitable for common immunoassays such as direct or indirect ELISA, sandwich immunoassays and Western blotting. The antibodies are specific to either different hemagglutinin proteins or influenza A nucleoprotein and can be used to detect these antigens from different biological samples such as nasal aspirates and swabs, cell lysates etc. As MAbs do not have cross-reactivity to the influenza B virus they can be used for differentiation between influenza A and influenza B. Antibodies specific to influenza A NP (Cat.# 3IN5) We provide five different MAbs that are specific to influenza type A nucleoprotein. The antibodies were raised against a H1N1 strain. All of the MAbs detect NP with high specificity and do not cross-react with influenza B nucleoprotein. Anti-NP MAbs equally detect different strains of influenza A in ELISA. An example of a titration curve with the MAb InA108 is provided in Figure 1.

2,500 3.0 2,000 2.5 A, 490nm 1,500 1,000 OD 0 2.0 1.5 1.0 0,500 0,000 1 10 100 1000 10000 100000 MAb concentration (ng/ml) 0.5 0.0 A (H1N1) A (H3N2) 0.001 0.01 0.1 1 Concentration of MAb F8 (μg/ml) Figure 1. Titration curve of the MAb InA108 that is specific to NP of the influenza A virus in indirect ELISA. Antigen: Influenza A/New Caledonia//99 (H1N1); 0.2 μg/well. Quantitative NP sandwich immunoassays. We tested all MAbs as capture and detection antibodies in sandwich immunoassays. All of the pairs detect nucleoprotein of different influenza A strains. The recommended pairs InA108 InA2 and InA180 InA2 are able to detect the nucleoprotein equally in strains H1N1 and H3N2. The calibration curve for InA108 InA2 is provided in Figure 2. Figure 3. Specific activity of the MAb F8 in ELISA with the purified virus antigens A H1N1 and H3N2. NP immunodetection in Western blotting. The MAbs InA108 and InA2 can be used for the detection of nucleoprotein in Western Blotting after SDS- PAGE in reducing conditions. The detection of two different influenza A strains with the MAb InA108 is shown in Figure 4. kda 66 1 2 Figure 2. A calibration curve for the influenza A sandwich fluoroimmunoassay using the MAb pair InA108-InA2 that is specific to the nucleoprotein of influenza A (Cat.# 3IN5). The antibody pair recognizes different influenza type A strains but does not detect influenza B strains. MAb F8. Based on our studies, the MAb F8 recognizes an epitope that can be found in nucleoproteins of influenza type A with different antigenic structure and species origin. We investigated 25 strains of human and avian influenza virus A that had been isolated during different epidemics between 1934 and 1993 and a specific reaction was observed in all of the cases. In addition, we investigated 265 samples of nasal washings from children during influenza outbreaks using direct immunofluorescence. Sensitivity and specificity of the influenza virus A detection was 60% and 98.2% respectively. The titration curve of MAb F8 is shown in Figure 3. Figure 4. Immunodetection of the influenza A viruses using anti-np monoclonal antibody InA108 in Western blotting after SDS-PAGE in reducing conditions. Antigens 1 μg/well, MAb InA108 5 μg/ml. Anti-mouse IgG conjugated with HRP was used as the secondary antibody. Lane 1 Influenza A/NewCaledonia//99 (H1N1). Lane 2 Influenza A/Shangdong/9/93 (H3N2). Antibodies specific to influenza A H1 (Cat.# 3AH1 and 3IH4) We provide five MAbs that are specific to hemagglutinin H1. Four antibodies (Cat.# 3AH1) were raised against a purified influenza A strain A/New Caledonia//99 (H1N1). One antibody (Cat.# 3IH4) was raised against an avian influenza virus strain A (H1N1). MAbs that are specific to H1 are able to detect a H1N1 strain in direct and indirect ELISA but are unable to detect a H3N2 strain. Titration curves of the MAb InA4 with two different influenza A strains are provided in Figure 5. 2

1.0 0.8 OD 0 0.6 0.4 0.2 0.0 0.001 0.01 0.1 1 Concentration of MAb C102 (μg/ml) Figure 5. Titration curves of the MAb InA4 that is specific to hemagglutinin H1. Quantitative H1 sandwich immunoassay. We tested all of the MAbs as capture and detection antibodies in sandwich type fluoroimmunoassays. The pairs InA4 InA134 and InA InA134 were able to detect a purified H1N1 strain with high specificity and sensitivity. Both pairs were able to detect the virus and recombinant hemagglutinin H1 and could be used in immunoassays that are specific to different H1-strains of influenza A. A calibration curve for InA InA134 is shown in Figure 6. Figure 7. Specific activity of the MAb C102 in ELISA with the purified influenza A virus H1N1. H1 immunodetection in Western blotting. Anti-H1 antibodies (Cat.# 3AH1) have been tested in Western blotting. All MAbs are suitable for the detection of H1 strains in Western blotting after SDS-PAGE in reducing conditions. An example using the MAb InA4 is shown in Figure 8. kda 1 2 kda 1 2 66 66 Figure 6. A calibration curve for influenza A sandwich fluoroimmunoassay using anti-haemagglutinin H1 antibodies. Capture: MAb Capture MAb: InA (1 µg/well) Detection MAb: Eu 3+ labelled InA134 (0.2 µg/well) Incubation time: min H1N1: Influenza A/New Caledonia//99 H3N2: Influenza A/Shangdong/9/93 Influenza B: mixture of Influenza B strains B/Qingdao/102/91, B/Tokio/53/99 and B/Victoria/504/00. MAb C102. This MAb (under Cat.# 3IH4) was obtained by using an avian influenza virus strain A (H1N1) as the immunogen. It is directed against a relatively conservative epitope of H1. The MAb C102 recognizes H1 from human and avian influenza viruses but it does not cross-react with H3 or other hemagglutinins. The MAb C102 could be used for the subtype differentiation of isolates. Meanwhile, the MAb C102 is also suitable for immunocytochemistry, haemagglutinin inhibition, ELISA and immunofluorescence studies. ELISA with the purified virus is provided in Figure 7. H1N1 H3N2 Figure 8. Immunodetection of the influenza A viruses using anti- HA1 and anti-ha3 MAbs in Western blotting after SDS-PAGE in reducing conditions. Strain H1N1: Influenza A/New Caledonia//99, strain H3N2: Influenza A/Shangdong/9/93, 1 μg/well. Lane 1 InA4 (anti-h1), lane 2 InA246 (anti-h3), 5 μg/ml. Anti-mouse IgG conjugated with HRP was used as the secondary antibody. Antibodies specific to influenza A H3 (Cat.# 3HG3) We provide two MAbs that are specific to hemagglutinin H3. The antibodies were raised against the purified influenza A strain A/Shangdong/9/93 (H3N2). MAbs that are specific to H3 are able to detect a H3N2 strain in direct and indirect ELISA but do not detect a H3N2 strain. Titration curves of the MAb InA246 with two different influenza A strains are provided in Figure 9. 3

A, 0nm 4,0 3,5 3,0 2,5 2,0 1,5 H7N7 virus recombinant H7 H1N1 virus H3N2 virus H2N2 virus Parainfluenza virus 1,0 0,5 Figure 9. Titration curves of the MAb InA246 that is specific to hemagglutinin H3. H3 immunodetection in Western blotting. Both of the MAbs detect influenza A H3 strains in Western blotting after SDS-PAGE in reducing conditions. An example using the MAb InA246 is shown in Figure 8. Antibodies specific to influenza A H5 (Cat.# 3H5N) Avian influenza viruses which usually refer to the influenza A viruses occur naturally in birds and cause avian influenza infection. It is only strains with hemagglutinin H5 and H7 subtypes that can cause highly pathogenic avian influenza which is extremely contagious and rapidly fatal in susceptible avian species. When highly pathogenic influenza H5 viruses cause outbreaks, the mortality rate among poultry is usually between 90 % - 100 %. In addition to birds, H5 viruses can cause severe infections in humans. We provide seven different MAbs that are specific to H5. The antibodies were obtained by using a purified avian influenza virus type A (H5N1) as an immunogen. Antibodies specific to influenza A H7 (Cat.# 3HI7) We provide three MAbs that are specific to H7. The antibodies were raised against purified Influenza A/Netherlands/219/03 H7N7 virus. All of the MAbs detect influenza A H7 hemagglutinin in direct and indirect ELISA. We investigated the cross-reactivity of the MAbs to other influenza A H subtypes: Influenza A H1N1 (strain A/New Caledonia//99), Influenza A H2N2 (strain A/Japan/5/57), Influenza A H3N2 (strain A /Panama/07/99), as well as to the parainfluenza virus (type 1 Sendai). All of the MAbs demonstrated high specificity to H7 and did not bind to other tested viruses. Cross-reactivity data with the MAb InA334 is provided in Figure 10 and show that the antibody only reacts with H7. Figure 10. Titration curve of the MAb InA334 that is specific to haemagglutinin H7 in indirect ELISA. Viral antigens 0 ng/well and recombinant H7 (A/Chicken/Netherlands/1/03; a.a.r. 17-527) 10 ng/well. H7 quantitative sandwich immunoassay. All of the MAbs were tested in sandwich type immunoassays as either capture or detection MAbs. The best pairs of MAbs were selected based on their ability to detect influenza A H7 with high sensitivity using the purified strain of Influenza A/Netherlands/219/03 H7N7 and recombinant H7 as antigens. We recommend using the pairs InA334 InA331 and InA334 InA414. The calibration curves for InA334 InA331 are provided in Figure 11. A CPS B 100 000 10 000 1 000 1 000 000 CPS 0,0 0 1 10 100 1 000 10 000 100 10 100 1 000 10 000 100 000 100 000 10 000 1 000 InA334, ng/ml Influenza A H7N7 (ng/ml) 100 0 1 10 100 1 000 10 000 Recombinant H7 (ng/ml) Figure 11. Calibration curves for influenza A haemagglutinin H7 in sandwich fluoroimmunoassays. Capture MAb: InA334 (1 μg/well) Detection MAb: Eu 3+ labelled InA331 (0.1 μg/well) Incubation time: min A) Influenza A/Netherlands/219/03 (H7N7) B) Recombinant H7 (A/Chicken/Netherlands/1/03; a.a.r. 17-527) 4

Influenza A antigens We provide nine different influenza A strains (H1 and H3) as antigens. The viruses are purified from the allantoic fluid of 10-12 day old embryonated chicken eggs that are inoculated with different influenza A strains and inactivated with thimerosal and beta propiolactone treatment. The purity of all products is >90 %. These antigens could be used in the detection of antibodies to the influenza A viruses in ELISA, hemagglutination inhibition tests and Western blotting. The antigens do not cross-react in ELISA with MAbs that are specific to influenza A of other HA subtypes or with MAbs which are specific to influenza B HA or NP. In the hemagglutination inhibition test, the antigens do not cross-react with antisera to different influenza A or B subtypes (Table 1 summarizes the cross-reactivity data for two of the antigens). Table 1. Hemagglutination test of selected influenza A antigens. H1N1 and H3N2 antigens are only detected with antiserum raised against the corresponding subtype and not with other antisera. Virus A/New Caledonia//99 (H1N1) Rabbit antisera to A/St.Petersburg/186/00 (H3N2) A/Singapore/1/57 (H2N2) A/swine/16/31 (Hsw1N1) A/New Caledonia//99 (H1N1) 640 <10 <10 <10 <10 A/Panama/07/99 (H3N2) <10 3 <10 <10 <10 B/Tokio/53/99 MONOCLONAL ANTIBODIES Product name Cat. # MAb Subclass Remarks Influenza A nucleoprotein 3IN5 F8 IgG2a EIA, IHC InA108 IgG1 EIA, WB InA180 IgG3 EIA InA224 IgG1 EIA InA2 IgG2b EIA, WB Influenza A haemagglutinin 3IH4 C102 IgG1 EIA, IF, HIT, IHC, haemagglutinin H1 Influenza A haemagglutinin H1 3AH1 InA4 IgG1 EIA, WB InA IgG1 EIA, WB InA134 IgG1 EIA, WB InA139 IgG1 EIA, WB Influenza A haemagglutinin H3 3HG3 InA227 IgG1 EIA, WB InA246 IgG2a EIA, WB Influenza A haemagglutinin H5 3H5N 15A6 IgG2a EIA, HIT, Dot blot 18D5 IgG2a EIA, HIT, Dot blot 19C11 IgG2a EIA, HIT, Dot blot 8D2 IgG2a EIA, HIT, Dot blot 6C8 IgG1 EIA, HIT 1C7 IgG2a EIA, HIT 1B4 IgG2a EIA Influenza A haemagglutinin H7 3HI7 InA331 IgG1 EIA InA334 IgG1 EIA InA414 IgG2b EIA ANTIGENS Product name Cat. # Purity Source Influenza A (H1N1) virus 8IN73 >90% A/Taiwan/1/86 Influenza A (H1N1) virus-2 8IN73-2 >90% A/Beijing/262/95 Influenza A (H1N1) virus-3 8IN73-3 >90% A/New Caledonia//99 Influenza A (H1N1) virus-4 8IN73-4 >90% A/Solomon Islands/03/06 Influenza A (H3N2) virus 8IN74 >90% A/Shangdong/9/93 Influenza A (H3N2) virus-1 8IN74-1 >90% A/Panama/07/99 Influenza A (H3N2) virus-2 8IN74-2 >90% A/Kiev/1/94 Influenza A (H3N2) virus-3 8IN74-3 >90% A/Wisconsin/67/05 Influenza A (H3N2) virus-4 8IN74-4 >90% A/Brisbane/10/07 5

Influenza B monoclonal antibodies HyTest offers a panel of monoclonal antibodies that are specific to influenza B NP, HA and matrix protein 1 (M1).These MAbs work with high affinity and specificity in different immunoassays including direct or indirect ELISA, sandwich immunodetection systems, as well as in Western blotting. Antibodies specific to influenza B NP (Cat.# 3IF18 and RIF17) We provide several MAbs that are specific to influenza B NP. The MAb R2/3 (Cat.# RIF17) is produced in vitro. The antibodies were raised against the purified influenza virus type B. They are highly specific to influenza B nucleoprotein and they do not cross-react with influenza A NP or other viral proteins that were tested. The low detection limit of our MAbs enables the detection of the virus even in samples with a low influenza B titer. Furthermore, the MAbs can be utilized in rapid influenza B assays. Table 2 shows the epitope specificities of the MAbs and antibody pair recommendations are provided in Table 3. Table 2. Epitope specificities of MAbs that are specific to influenza B nucleoprotein. Epitope Fragment 1: (1-80 a.a.r.) MAbs InB12, InB36 Fragment 2: (1-0 a.a.r.) InB27, InB64 Fragment 3: (240-3 a.a.r.) InB4, InB210, 2/3 Fragment 4: (480-560a.a.r) InB114, InB213 Table 3. Antibody pair recommendations for influenza B nucleoprotein sandwich immunoassays. Capture InB12 InB12 InB36 Detection InB27 InB64 InB64 All anti-np MAbs detect different strains of influenza B in direct and indirect ELISA. The titration curves of the MAb InB114 are shown in Figure 12. Influenza B quantitative sandwich immunoassay. The MAbs were tested in sandwich type immunoassays as capture and detection MAbs. Recommended pairs (see Table 3) were selected based on their ability to detect several influenza B strains and recombinant influenza B NP with equal specificity and high sensitivity. The strains that were tested were Influenza B/Leningrad/86/93, Influenza B/Tokyo/53/99 and Influenza B/Victoria/504/00. The calibration curve for the pair InB36 InB64 is shown in Figure 13. CPS Figure 12. Titration curves of the MAb InB114 that is specific to influenza B NP in indirect (A) and direct (B) ELISA. Influenza B: Influenza B/Tokyo/53/99 (A: 0.5 μg/well, B: 0.2 μg/well). Influenza A: Mixture of strains A/Shangdong/9/93 and A/New Caledonia//99 (0.5 μg/well). CPS A, 490nm 2,500 2,000 1,500 1,000 0,500 0,000 100000 10000 100000 10000 1000 1000 100 100 Influenza B Influenza A 0,1 1 10 100 1000 10000 B A MAb concentration (ng/ml) B/Tokyo/53/99 0,01 0,1 1 10 100 1000 InB114-Eu chelate concentration (ng/ml) 10 100 1 000 10 000 100 000 Influenza B virus (ng/ml) Figure 13. Calibration curve for influenza B NP in a sandwich fluoroimmunoassay. Capture MAb: InB36 (1 μg/well) Detection MAb: Eu 3+ labelled InB64 (0.2 μg/well) Incubation time: min Antigen: Influenza B/Tokio/53/99. MAb R2/3. This MAb (Cat.# RIF17) is produced in vitro. The antibody detects the nucleoprotein of the virus and it has been tested with several influenza B strains (see Figure 14). No cross-reactivity was detected when it was tested with nine influenza A strains, three parainfluenza strains, adenovirus (type 6) or respiratory syncytial virus. 6

1,000 2.5 B/Tokio/53/99 B/Victoria/504/00 0,800 2 B/Florida/07/04 A, 405 nm 1.5 1 B/Florida/04/06 B/Malaysia/2506/04 A, 490nm 0,600 0,400 0,0 Influenza B/Tokyo/53/99 Influenza B/Leningrad/86/93 Influenza B/Victoria/504/00 Influenza A mixture 0.5 0,000 0,1 1 10 100 1000 10000 100000 MAb concentration (ng/ml) 0 1 0.1 0.01 MAb conc. (µg/ml) 0.001 Figure 14. A direct ELISA analysis of the anti-influenza B group antigen (Cat.# RIF17) with different influenza B strains. Antigens were absorbed to the plate in 5 μg/ml concentration and antibody binding was tested using a dilution series of the antibody from 1 μg/ml to 1 ng/ml concentration. Influenza B NP immunodetection in Western blotting. MAbs detect NP of influenza B in Western blotting after SDS-PAGE in reducing and non-reducing conditions. Western blotting using MAbs InB27 and InB63 is shown in Figure 15. Figure 16. Titration curves of the MAb InB190 that is specific to influenza B HA in indirect ELISA. Antigens: 0.5 µg/well. Influenza A was a mixture of strains A/Shangdong/9/93 and A/New Caledonia//99. kda 1 2 3 66 Figure 17. Immunodetection of influenza B HA2 using the MAb InB190 in Western blotting. Lane 1: Influenza B/Tokio/53/99, 1 μg/well, lane 2: Influenza B/Leningrad/86/93, 1 μg/well, lane 3: Influenza B/Victoria/ 504/00, 1 μg/well, Primary antibody: MAb InB190 (3 μg/ml), Secondary antibody: Anti-mouse IgG conjugated with HRP. kda 66 InB27 InB64 Figure 15. Immunodetection of influenza B NP in Western blotting after PAGE in reducing conditions. Antigen: Influenza B/Tokio/53/99, 1 μg/well. Antibodies InB27 and InB64, 5 μg/ml. Anti-mouse IgG conjugated with HRP was used as the secondary antibody. Antibodies specific to influenza B M1 (Cat.# 3BM17) Antibodies specific to influenza B HA (Cat.# 3GH9) We provide two MAbs that are specific to influenza B matrix protein M1. The MAbs detect M1 protein in direct and indirect ELISA. The titration curve of the MAb InB4 is shown in Figure 18. M1 immunodetection in Western blotting. Both MAbs detect M1 in Western blotting after SDS-PAGE in reducing conditions. We provide two MAbs that are specific to hemagglutinin HA2. Both MAbs equally detect the hemagglutinin of different influenza B strains in direct and indirect ELISA. The titration curves of the MAb InB190 are shown in Figure 16. HA immunodetection in Western blotting. All of the MAbs detect the hemagglutinin HA2 chain of different influenza B strains in Western blotting after SDS-PAGE in reducing conditions. Western blotting using the MAb InB190 is shown in Figure 17. A, 490nm 2,500 2,000 1,500 1,000 0,500 0,000 1 10 100 1000 10000 100000 MAb concentration (ng/ml) Figure 18. Titration curve of the MAb InB4 that is specific to influenza B M1 in indirect ELISA. Antigen: Influenza B/Tokyo/53/99, 0.5 μg/well. 7

Influenza B antigens We provide five different influenza B strains as antigens. The viruses are purified from the allantoic fluid of 10-12 day old embryonated chicken eggs that are inoculated with influenza B strains and inactivated with thimerosal and beta propiolactone treatment. The purity of all products is >90 %. These antigens could be used in the detection of antibodies to influenza B viruses in ELISA, hemagglutination inhibition tests and Western blotting. Influenza B antigens do not cross-react in ELISA with MAbs that are specific to influenza A hemagglutinin subtypes (H1N1 or H3N2). In the hemagglutination inhibition test, the antigens do not cross-react with antisera to influenza A H1N1 or H3N2 viruses (Table 4 summarizes the cross-reactivity data for two antigens) Table 4. Hemagglutination test of selected influenza B antigens. The antigens are only detected with antiserum raised against the corresponding virus and not with other antisera. Rabbit antisera to B/Tokio/53/99 B/Victoria/504/00 A/New Caledonia//99 A/St.Petersburg/186/00 A/swine/16/31 Figure 19. Electron microscopic image of the influenza B virus. (The diameter of the virus particles is 100-1 nm. Magnification 110,000x. Virus B/Tokio/53/99 3 <10 <10 <10 <10 B/Victoria/504/00 <10 3 <10 <10 <10 MONOCLONAL ANTIBODIES Product name Cat. # MAb Subclass Remarks Influenza B haemagglutinin 3BH9 InB18 IgG2a EIA, WB, haemagglutinin 2 (HA2) InB190 IgG2b EIA, WB, haemagglutinin 2 (HA2) Influenza B matrix protein M1 3BM17 InB4 IgG1 EIA, WB InB15 IgG1 EIA, WB Influenza B group antigen 3IF18 2/3 IgG2a EIA, WB, IF, nucleoprotein InB12 IgG2b EIA, WB, nucleoprotein InB27 IgG1 EIA, WB, nucleoprotein InB36 IgG1 EIA, WB, nucleoprotein InB64 IgG1 EIA, WB, nucleoprotein InB114 IgG1 EIA, WB, nucleoprotein InB4 IgG1 EIA, WB, nucleoprotein InB210 IgG1 EIA, WB, nucleoprotein InB213 IgG1 EIA, WB, nucleoprotein Influenza B group antigen, in vitro RIF17 R2/3 IgG2a EIA, WB, nucleoprotein ANTIGENS Product name Cat. # Purity Source Influenza B virus-2 8IN75-2 >90% B/Tokio/53/99 Influenza B virus-3 8IN75-3 >90% B/Victoria/504/00 Influenza B virus-4 8IN75-4 >90% B/Malaysia/2506/04 Influenza B virus-5 8IN75-5 >90% B/Florida/07/04 Influenza B virus-6 8IN75-6 >90% B/Florida/04/06 HyTest Ltd Intelligate 1, 6 th floor, Joukahaisenkatu 6 FI-5 Turku, FINLAND Tel. +358 2 512 0900, Fax +358 2 512 0909 E-mail: hytest@hytest.fi www.hytest.fi October 17 HyTest Ltd. All rights reserved.